The US Food and Drug Administration has granted approval to the monoclonal antibody Herceptin (trastuzumab) in combination with chemotherapy for the treatment of a gene-specific stomach cancer, HER-2 positive metastatic stomach cancer.
The FDA's approval pertains to the use of Herceptin in conjunction with the platinum-based chemotherapeutic drug cisplatin and either capecitabine or 5-fluorouracil in patients who have not previously received medication to treat their stomach cancer.
Herceptin was first approved for patients with HER-2 positive metastatic breast cancer. The FDA's wider approval of Herceptin for stomach cancer is based on the results of the ToGa Phase III study, which suggested that patients with HER-2 positive stomach tumors lived longer when given Herceptin along with combination chemotherapy (compared to receiving only the chemotherapy).
CANCER TYPE(S)
Metastatic stomach cancer
TREATMENT TYPE(S)
Targeted treatment
Source
Medical News Today
The information provided on CancerTreatment.net is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her health professional. This information is solely for informational purposes and does not constitute the practice of medicine. We encourage all visitors to see a licensed physician or nutritionist if they have any concerns regarding health issues related to diet, personal image and any other topics discussed on this site. Neither the owners or employees of CancerTreatment.net nor the author(s) of site content take responsibility for any possible consequences from any treatment, procedure, exercise, dietary modification, action or application of medication which results from reading this site. Always speak with your primary health care provider before engaging in any form of self treatment. Please see our Legal Statement for further information.
